[go: up one dir, main page]

MA31359B1 - Pyrimidinyl-pipérazines utiles en tant que ligands des récepteurs d3/d2 - Google Patents

Pyrimidinyl-pipérazines utiles en tant que ligands des récepteurs d3/d2

Info

Publication number
MA31359B1
MA31359B1 MA32320A MA32320A MA31359B1 MA 31359 B1 MA31359 B1 MA 31359B1 MA 32320 A MA32320 A MA 32320A MA 32320 A MA32320 A MA 32320A MA 31359 B1 MA31359 B1 MA 31359B1
Authority
MA
Morocco
Prior art keywords
ligands
receptors
pyrimidinyl
piperazines useful
relates
Prior art date
Application number
MA32320A
Other languages
Arabic (ar)
English (en)
Inventor
Szalai Gizella Bartáné
Csongor Éva Ágainé
György Domány
István Gyertyán
Béla Kiss
Judit Laszy
Katalin Sághy
Éva Schmidt
Sándor Farkas
Zsolt Komlódi
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MA31359B1 publication Critical patent/MA31359B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux ligands des récepteurs d3 et d2 de la dopamine répondant à la formule (i), dans laquelle rl, r2 et q sont tels que décrits ici, et/ou des isomères géométriques et/ou des stéréoisomères et/ou des diastéréomères et/ou des sels et/ou des hydrates et/ou des solvates et/ou des polymorphes desdits ligands. L'invention concerne également des procédés de préparation desdits ligands, des compositions les contenant et leur utilisation pour traiter et/ou prévenir les troubles nécessitant une modulation des récepteurs de la dopamine.
MA32320A 2007-04-11 2009-11-02 Pyrimidinyl-pipérazines utiles en tant que ligands des récepteurs d3/d2 MA31359B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700269A HUP0700269A2 (en) 2007-04-11 2007-04-11 Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use
PCT/HU2008/000032 WO2008125891A2 (fr) 2007-04-11 2008-04-10 Pyrimidinyl-pipérazines utiles en tant que ligands des récepteurs d3/d2

Publications (1)

Publication Number Publication Date
MA31359B1 true MA31359B1 (fr) 2010-05-03

Family

ID=38336883

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32320A MA31359B1 (fr) 2007-04-11 2009-11-02 Pyrimidinyl-pipérazines utiles en tant que ligands des récepteurs d3/d2

Country Status (36)

Country Link
EP (1) EP2132185B1 (fr)
JP (1) JP4580464B2 (fr)
KR (1) KR101540821B1 (fr)
CN (1) CN101652351B (fr)
AP (1) AP2460A (fr)
AT (1) ATE518843T1 (fr)
AU (1) AU2008237696B2 (fr)
BR (1) BRPI0809641A2 (fr)
CA (1) CA2682817C (fr)
CO (1) CO6241116A2 (fr)
CR (1) CR11071A (fr)
CU (1) CU23853B1 (fr)
CY (1) CY1111962T1 (fr)
DK (1) DK2132185T3 (fr)
EA (1) EA016174B1 (fr)
EC (1) ECSP099702A (fr)
ES (1) ES2370748T3 (fr)
GE (1) GEP20115272B (fr)
HK (1) HK1134491A1 (fr)
HR (1) HRP20110785T8 (fr)
HU (1) HUP0700269A2 (fr)
IL (1) IL200801A0 (fr)
MA (1) MA31359B1 (fr)
MX (1) MX2009010896A (fr)
MY (1) MY148384A (fr)
NI (1) NI200900179A (fr)
NZ (1) NZ579754A (fr)
PL (1) PL2132185T3 (fr)
PT (1) PT2132185E (fr)
RS (1) RS51979B (fr)
SI (1) SI2132185T1 (fr)
TN (1) TN2009000386A1 (fr)
TW (1) TWI445534B (fr)
UA (1) UA103748C2 (fr)
WO (1) WO2008125891A2 (fr)
ZA (1) ZA200906543B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9091489B2 (en) 2010-05-14 2015-07-28 Paragon Space Development Corporation Radiator systems
AU2011268073B2 (en) * 2010-06-18 2015-07-16 Takeda Pharmaceutical Company Limited D2 antagonists, methods of synthesis and methods of use
US9376396B2 (en) * 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
HU229987B1 (en) * 2012-11-21 2015-04-28 Richter Gedeon Nyrt Process for the preparation of pyrimidinyl-piperazines
US10870660B2 (en) 2016-07-28 2020-12-22 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
JP7250405B2 (ja) * 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
JPWO2019146739A1 (ja) 2018-01-26 2021-01-07 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する縮環化合物
CN111770754B (zh) * 2019-01-30 2023-09-19 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
WO2024072930A1 (fr) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agonistes partiels du récepteur d3/d2 de la dopamine destinés au traitement de troubles neuropsychiatriques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2311776A1 (fr) * 1975-05-23 1976-12-17 Sogeras Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation
US4957921A (en) 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
US5047406A (en) * 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (fr) * 2006-06-22 2007-12-26 Bioprojet (Aza)cyclohexanes carbonylées comme ligands du récepteur D3 de la dopamine

Also Published As

Publication number Publication date
CA2682817A1 (fr) 2008-10-23
MX2009010896A (es) 2009-12-14
AU2008237696B2 (en) 2013-03-14
TN2009000386A1 (en) 2010-12-31
CY1111962T1 (el) 2015-11-04
RS51979B (en) 2012-02-29
EA016174B1 (ru) 2012-02-28
TW201002328A (en) 2010-01-16
WO2008125891A3 (fr) 2009-01-08
HU0700269D0 (en) 2007-05-29
HK1134491A1 (en) 2010-04-30
GEP20115272B (en) 2011-08-25
CU20090161A7 (es) 2011-09-21
BRPI0809641A2 (pt) 2014-11-11
CN101652351A (zh) 2010-02-17
HUP0700269A2 (en) 2009-04-28
EP2132185A2 (fr) 2009-12-16
KR20100082713A (ko) 2010-07-19
EA200901391A1 (ru) 2010-02-26
ES2370748T3 (es) 2011-12-22
CR11071A (es) 2009-11-20
ZA200906543B (en) 2010-06-30
HRP20110785T8 (en) 2012-04-30
NI200900179A (es) 2010-06-30
AP2460A (en) 2012-09-13
UA103748C2 (uk) 2013-11-25
CN101652351B (zh) 2012-07-04
JP2010523642A (ja) 2010-07-15
PT2132185E (pt) 2011-11-21
PL2132185T3 (pl) 2011-12-30
DK2132185T3 (da) 2011-10-03
CU23853B1 (es) 2012-10-15
ECSP099702A (es) 2009-11-30
EP2132185B1 (fr) 2011-08-03
MY148384A (en) 2013-04-15
TWI445534B (zh) 2014-07-21
CO6241116A2 (es) 2011-01-20
SI2132185T1 (sl) 2011-11-30
CA2682817C (fr) 2015-11-24
ATE518843T1 (de) 2011-08-15
AU2008237696A1 (en) 2008-10-23
IL200801A0 (en) 2010-05-17
WO2008125891A2 (fr) 2008-10-23
HRP20110785T1 (hr) 2011-11-30
NZ579754A (en) 2011-11-25
KR101540821B1 (ko) 2015-07-30
JP4580464B2 (ja) 2010-11-10
AP2009004970A0 (en) 2009-10-31

Similar Documents

Publication Publication Date Title
MA31359B1 (fr) Pyrimidinyl-pipérazines utiles en tant que ligands des récepteurs d3/d2
MA31419B1 (fr) Derives de pyridine
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA31894B1 (fr) Composes organiques
MA30932B1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
TN2009000112A1 (fr) Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
BRPI0612926B8 (pt) compostos fluorados de 4-(2-amino-1-hidroxietila)fenol como agonistas de receptores b2 adrenérgicos, composição farmacêutica, combinação e uso de um composto
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA31766B1 (fr) Composés organiques
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA31586B1 (fr) Dérivés d'alcools alkyliques de 1-phényl-2-pyridinyle en tant qu'inhibiteurs de la phosphodiestérase
MA31597B1 (fr) Nouveaux herbicides
MA28747B1 (fr) Dérivés de pyridine
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA28269A1 (fr) Arylpyrazoles substitués servant d'agents parasiticides
MA30427B1 (fr) Derives bicycliques utilises comme inhibiteurs de cetp
MA32965B1 (fr) Derives de sulfonamides
MA29926B1 (fr) Derives de pyrazine